ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jiangsu HengRui Medicine and HUTCHMED side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Jiangsu HengRui MedicineHUTCHMED
studies on the registry1,066119
open to participants now30713
phase 3 studies under way1059
reach primary completion within a year1302
programswith a study of their own in two years156+1 named only8

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJiangsu HengRui MedicineHUTCHMED
Phase 1

Jiangsu HengRui Medicine: 53 of its 156 programs at phase 1

  1. Rifampinphase 1
  2. HRS-5817phase 1
  3. HRS-2189phase 1
  4. SHR-2017phase 1
  5. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1

and 48 more — sign in to see them all

34%

HUTCHMED: 1 of its 8 programs at phase 1

  1. sovleplenib acetatephase 1
13%
Phase 2

Jiangsu HengRui Medicine: 50 of its 156 programs at phase 2

  1. SHR-1139phase 2
  2. SHR-1826phase 2
  3. SHR-9839phase 2
  4. SHR-2173phase 2
  5. HRS-4508phase 2

and 45 more — sign in to see them all

32%
38%
Phase 3

Jiangsu HengRui Medicine: 51 of its 156 programs at phase 3

  1. adebrelimabphase 3
  2. trastuzumab rezetecanphase 3
  3. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3
  4. ribupatidephase 3
  5. notiretatug rezetecanphase 3

and 46 more — sign in to see them all

33%

HUTCHMED: 4 of its 8 programs at phase 3

  1. ranosidenibphase 3
  2. sovleplenibphase 3
  3. fanregratinibphase 3
  4. BTK Inhibitor HMPL-760phase 3
50%
Approved, new studies

Jiangsu HengRui Medicine: 2 of its 156 programs at approved, new studies

  1. vunakizumabapproved, new study
  2. remimazolam tosylateapproved, new study
1%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jiangsu HengRui Medicine75 readouts · 11 phase 3

Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion

  1. HRS-1780phase 3 · Nov 0 · NCT07470983
  2. SHR-1681phase 2 · Nov 0 · NCT06737731

Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3

  1. adebrelimabphase 3 · Dec 0 · NCT05482568
  2. Anti-DLL3 Antibody-drug Conjugate IDE849phase 1 · Dec 0 · NCT06443489
  3. BP102phase 3 · Dec 0 · NCT06915142
  4. drotokibartphase 3 · Dec 0 · NCT07688772
  5. HRS-1596phase 1 · Dec 0 · NCT07841860

and 27 more — sign in to see them all

Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. RSS0393phase 3 · Jan 0 · NCT07543224
  2. SHR 3201phase 1 · Jan 0 · NCT07889349
  3. SHR-4375phase 2 · Jan 0 · NCT07298772
  4. HRS-5817phase 1 · Jan 30 · NCT07238647

Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion

  1. FH-006phase 3 · Feb 0 · NCT07136142
  2. HRS-5346phase 2 · Feb 0 · NCT07767513
  3. HRS-8080phase 3 · Feb 0 · NCT07876596
  4. KRAS G12D Inhibitor HRS-4642phase 3 · Feb 0 · NCT07906691
  5. RSS0343phase 2 · Feb 0 · NCT07940829

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3 · Mar 0 · NCT06929624
  2. HRS-1893phase 3 · Mar 0 · NCT07269717
  3. HRS-4139phase 1 · Mar 0 · NCT07802964
  4. HRS-4729phase 2 · Mar 0 · NCT07690826
  5. ivarmacitinibphase 3 · Mar 0 · NCT07251595

and 3 more — sign in to see them all

Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion

  1. HRS-4029phase 2 · Apr 0 · NCT07739160
  2. HRS-5632phase 2 · Apr 0 · NCT07185776
  3. SHR-1703phase 3 · Apr 0 · NCT07701239
  4. SHR-2173phase 2 · Apr 0 · NCT07354932
  5. SHR-4602phase 2 · Apr 0 · NCT06704828

and 1 more — sign in to see them all

Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion

  1. SHR-4712phase 1 · May 0 · NCT06993116

Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-7249phase 2 · Jun 0 · NCT07308392
  2. HRS8179phase 3 · Jun 0 · NCT06732648
  3. SHR-1819phase 3 · Jun 0 · NCT07321951
  4. SHR-1918phase 3 · Jun 0 · NCT07308392
  5. SHR-9803phase 2 · Jun 0 · NCT06906731

Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion

  1. Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Jul 0 · NCT07682272
  2. ruzinuradphase 3 · Jul 0 · NCT07362355
  3. aumolertinibphase 3 · Jul 30 · NCT05503888
  4. retlirafusp alfaphase 3 · Jul 30 · NCT05503888
  5. SHR-9539phase 1 · Jul 31 · NCT06484777
·

Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-4508phase 2 · Sep 0 · NCT07003321
  2. garetatug rezetecanphase 3 · Sep 20 · NCT06649292

Jiangsu HengRui Medicine, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HRS-5965phase 3 · Oct 0 · NCT07014826
  2. SHR-2524phase 1 · Oct 0 · NCT07478302
HUTCHMED1 readouts · 0 phase 3·

HUTCHMED, Dec ’26: 1 program whose next study reaches primary completion

  1. ranosidenibphase 3 · Dec 0 · NCT07025018
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jiangsu HengRui Medicine

New programs 11

Reached a new phase 4

  • SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
  • HRS-6209phase 3 · Oct 14 · Breast Neoplasms
  • HRS-7172phase 2 · Sep 2 · Lung Neoplasms
  • FH-006phase 3 · Aug 25 · Lung Neoplasms

Study stopped 0

None

Primary completion later 6

HUTCHMED

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionJiangsu HengRui MedicineHUTCHMED
Lymphoma, B-Cellboth · compare here

Jiangsu HengRui Medicine in Lymphoma, B-Cell: 2 programs

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3
  2. SHR-3079phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma, B-Cell in search

HUTCHMED in Lymphoma, B-Cell: 1 program

  1. BTK Inhibitor HMPL-760phase 3

Their studies: HUTCHMED’s studies of Lymphoma, B-Cell in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Jiangsu HengRui Medicine in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. hetrombopag olaminephase 3
  2. SHR-2173phase 2

Their studies: Jiangsu HengRui Medicine’s studies of Purpura, Thrombocytopenic, Idiopathic in search

HUTCHMED in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. sovleplenibphase 3

Their studies: HUTCHMED’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Lymphomaboth · compare here

Jiangsu HengRui Medicine in Lymphoma: 1 program

  1. zeprumetostatphase 3

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma in search

HUTCHMED in Lymphoma: 1 program

  1. sovleplenibphase 3

Their studies: HUTCHMED’s studies of Lymphoma in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Jiangsu HengRui Medicine in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. Anti-CD79b Antibody-drug Conjugate SHR-A1912phase 3

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma, Large B-Cell, Diffuse in search

HUTCHMED in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. BTK Inhibitor HMPL-760phase 3

Their studies: HUTCHMED’s studies of Lymphoma, Large B-Cell, Diffuse in search

Lymphoma, Non-Hodgkinboth · compare here

Jiangsu HengRui Medicine in Lymphoma, Non-Hodgkin: 1 program

  1. HRS-3738phase 1

Their studies: Jiangsu HengRui Medicine’s studies of Lymphoma, Non-Hodgkin in search

HUTCHMED in Lymphoma, Non-Hodgkin: 1 program

  1. sovleplenibphase 3

Their studies: HUTCHMED’s studies of Lymphoma, Non-Hodgkin in search

Thrombocytopeniaboth · compare here

Jiangsu HengRui Medicine in Thrombocytopenia: 1 program

  1. hetrombopag olaminephase 3

Their studies: Jiangsu HengRui Medicine’s studies of Thrombocytopenia in search

HUTCHMED in Thrombocytopenia: 1 program

  1. sovleplenibphase 3

Their studies: HUTCHMED’s studies of Thrombocytopenia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Jiangsu HengRui Medicine 67 of 156 · HUTCHMED 6 of 8 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Jiangsu HengRui Medicine: 1).